294 related articles for article (PubMed ID: 17322388)
1. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.
Said N; Najwer I; Motamed K
Am J Pathol; 2007 Mar; 170(3):1054-63. PubMed ID: 17322388
[TBL] [Abstract][Full Text] [Related]
2. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
3. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
Said N; Motamed K
Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
[TBL] [Abstract][Full Text] [Related]
4. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.
Said NA; Najwer I; Socha MJ; Fulton DJ; Mok SC; Motamed K
Neoplasia; 2007 Jan; 9(1):23-35. PubMed ID: 17325741
[TBL] [Abstract][Full Text] [Related]
5. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells.
Yiu GK; Chan WY; Ng SW; Chan PS; Cheung KK; Berkowitz RS; Mok SC
Am J Pathol; 2001 Aug; 159(2):609-22. PubMed ID: 11485919
[TBL] [Abstract][Full Text] [Related]
6. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.
Bull Phelps SL; Carbon J; Miller A; Castro-Rivera E; Arnold S; Brekken RA; Lea JS
Am J Obstet Gynecol; 2009 Feb; 200(2):180.e1-7. PubMed ID: 18992864
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic Isoforms of SPARC Induce Adipose Stromal Cell Mobilization in Obesity.
Tseng C; Kolonin MG
Stem Cells; 2016 Jan; 34(1):174-90. PubMed ID: 26381424
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis.
Sangaletti S; Di Carlo E; Gariboldi S; Miotti S; Cappetti B; Parenza M; Rumio C; Brekken RA; Chiodoni C; Colombo MP
Cancer Res; 2008 Nov; 68(21):9050-9. PubMed ID: 18974151
[TBL] [Abstract][Full Text] [Related]
9. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
Brown TJ; Shaw PA; Karp X; Huynh MH; Begley H; Ringuette MJ
Gynecol Oncol; 1999 Oct; 75(1):25-33. PubMed ID: 10502421
[TBL] [Abstract][Full Text] [Related]
10. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
Shi Q; Bao S; Song L; Wu Q; Bigner DD; Hjelmeland AB; Rich JN
Oncogene; 2007 Jun; 26(28):4084-94. PubMed ID: 17213807
[TBL] [Abstract][Full Text] [Related]
11. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.
Chen J; Wang M; Xi B; Xue J; He D; Zhang J; Zhao Y
PLoS One; 2012; 7(8):e42413. PubMed ID: 22879971
[TBL] [Abstract][Full Text] [Related]
12. SPARC ameliorates ovarian cancer-associated inflammation.
Said NA; Elmarakby AA; Imig JD; Fulton DJ; Motamed K
Neoplasia; 2008 Oct; 10(10):1092-104. PubMed ID: 18813349
[TBL] [Abstract][Full Text] [Related]
13. Chaperone-like activity revealed in the matricellular protein SPARC.
Emerson RO; Sage EH; Ghosh JG; Clark JI
J Cell Biochem; 2006 Jul; 98(4):701-5. PubMed ID: 16598771
[TBL] [Abstract][Full Text] [Related]
14. SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
Tumbarello DA; Andrews MR; Brenton JD
PLoS One; 2016; 11(9):e0162698. PubMed ID: 27622658
[TBL] [Abstract][Full Text] [Related]
15. SPARC Controls Melanoma Cell Plasticity through Rac1.
Salvatierra E; Alvarez MJ; Leishman CC; Rivas Baquero E; Lutzky VP; Chuluyan HE; Podhajcer OL
PLoS One; 2015; 10(8):e0134714. PubMed ID: 26248315
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
Nagaraju GP; Dontula R; El-Rayes BF; Lakka SS
Carcinogenesis; 2014 May; 35(5):967-73. PubMed ID: 24675529
[TBL] [Abstract][Full Text] [Related]
17. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity.
Barker TH; Baneyx G; Cardó-Vila M; Workman GA; Weaver M; Menon PM; Dedhar S; Rempel SA; Arap W; Pasqualini R; Vogel V; Sage EH
J Biol Chem; 2005 Oct; 280(43):36483-93. PubMed ID: 16115889
[TBL] [Abstract][Full Text] [Related]
18. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
19. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis.
Girotti MR; Fernández M; López JA; Camafeita E; Fernández EA; Albar JP; Benedetti LG; Valacco MP; Brekken RA; Podhajcer OL; Llera AS
J Invest Dermatol; 2011 Dec; 131(12):2438-47. PubMed ID: 21850018
[TBL] [Abstract][Full Text] [Related]
20. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway.
Motamed K; Sage EH
J Cell Biochem; 1998 Sep; 70(4):543-52. PubMed ID: 9712151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
